Organogenesis will support initiatives to educate about diabetic foot ulcers, the leading cause of diabetes-related amputations
CANTON, Mass., June 21, 2018 /PRNewswire/ — Organogenesis Inc. – a leading regenerative medicine company committed to empowering healing – today announced it is a proud supporter of the American Diabetes Association (ADA). Organogenesis will support the production of an ADA scientific compendium focused on the latest scientific evidence related to the treatment of diabetic foot ulcers (DFUs), the leading cause of diabetes-related amputations in the United States.
Organogenesis will also host a corporate symposium, “Innovations in Diabetic Wound Healing,” at the ADA’s 78thScientific Sessions, held June 22-26 in Orlando, FL, and exhibit during the meeting trade show at Booth #616.
“As a global regenerative medicine company driven by a shared mission to empower healing, we work to provide opportunities for patients and health care professionals to learn more about state-of-the-art approaches to treat diabetic foot ulcers,” said Gary S. Gillheeney, Sr., President and CEO of Organogenesis. “We are happy to support the ADA and its work to help Americans living with diabetes.”